Literature DB >> 31955139

Biopharmaceutical classification of desloratadine - not all drugs are classified the easy way.

Katja Berginc1, Nadica Sibinovska1,2, Simon Žakelj2, Jurij Trontelj2, Igor Legen1.   

Abstract

The biopharmaceutical classification of drugs was designed as a basis for bio-waivers - a mechanism with the double ethical benefit of delivering new drug formulations to the market with less human testing and lower cost. However, many drugs defy simple classification because in vitro permeability and stability assessment can be challenging as shown in this study for desloratadine. Literature shows that desloratadine is highly soluble, while data on luminal stability and permeability are circumstantial. Combined with borderline bioavailability and not really known fraction of absorbed dose, desloratadine was found to be a good example for showing the innovative in vitro approaches necessary to unambiguously classify desloratadine according to Biopharmaceutical Classification System (BCS) guideline. Presented study undoubtedly confirmed that desloratadine solubility is high and dissolution is very rapid for immediate release reference tablets. We have demonstrated deslorata-dine stability under legally required conditions and also in more physiologically relevant media. High in vitro desloratadine permeability was confirmed using Caco-2 and Parallel Artificial Membrane Permeability Assay (PAMPA). Well-established in vitro model with rat intestinal tissue could not be used due to reasons elaborated in this paper.

Entities:  

Keywords:  BCS-based bio-waiver; desloratadine; dissolution; luminal stability; permeability

Year:  2020        PMID: 31955139     DOI: 10.2478/acph-2020-0006

Source DB:  PubMed          Journal:  Acta Pharm        ISSN: 1330-0075            Impact factor:   2.230


  1 in total

1.  A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.

Authors:  Tuba Reçber; Selin Seda Timur; Sevilay Erdoğan Kablan; Fatma Yalçın; Tutku Ceren Karabulut; R Neslihan Gürsoy; Hakan Eroğlu; Sedef Kır; Emirhan Nemutlu
Journal:  J Pharm Biomed Anal       Date:  2022-02-26       Impact factor: 3.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.